02 Sep 21 | US | Amgen and Hospira appear ready to settle the ongoing dispute relating to Neupogen® (filgrastim). The matter was due to go to a jury trial on 20 September 2021....
Pearce IP BioBlast®: w/e 10 September 2021
read more
Federal Court Confirms Higher Bar for Sufficiency and Support in Australian Patent Law
Nalco Patent Application Claiming Inhibitors of Silica Deposits Invalid: a Question of Scale
A recent decision of Justice Burley in the Federal Court of Australia confirms that the bar for sufficiency and support has actually been raised by Australia’s 2012 ‘Raising the...
Naomi Pearce recognised as a World Leading Patent Strategist by IAM
Pearce IP is proud to announce that Pearce IP’s Founding Principal and Executive Lawyer, Patent and Trade Mark Attorney, Naomi Pearce, has once again been recognised as a World...
Pearce IP BioBlast®: w/e 03 September 2021
26 Aug 21 | US | Two former executives of JHL Biotech plead guilty to conspiracy to steal trade secrets and commit wire fraud exceeding $101 million in the US District Court for...
Did pharmaceutical innovation contribute to the AI inventor controversy in Australia?
Australia was recently thrust into the global IP limelight when the Federal Court controversially determined that an artificial intelligence (AI) system, DABUS, can be an...
Pearce IP BioBlast®: w/e 27 August 2021
24 Aug 21 | UCB announced that it has gained EU marketing approval for Bimzelx® (bimekizumab), an IL-17A and IL-17F inhibitor indicated for the treatment of adults with moderate...
Pearce IP BioBlast®: w/e 20 August 2021
17 Aug 21 | US | The USPTO Patent Trial and Appeal Board (PTAB) will review Amgen’s US 8,273,707 Patent (related to NEULASTA® (pegfilgrastim) in an IPR challenge brought by...
Consider the Bar Raised for Sufficiency and Support: Nalco Patent Application Claiming Inhibitors of Silica Deposits Invalid
Cytec Industries Inc. v Nalco Company [2021] FCA 970
Date: 19 August 2021Court: Federal Court of AustraliaJudge: Burley J Background The ‘Bayer process’ has been used for over 130 years to extract alumina from bauxite to make...
PTEs in Australia – more hard lessons for patentees from the Federal Court
The Australian Federal Court has confirmed in Merck Sharp & Dohme Corp. v Sandoz Pty Ltd [2021] FCA 947 that, when a patent covers two pharmaceutical substances of the...
Pearce IP BioBlast®: w/e 13 August 2021
05 Aug 21 | A new study reported that the safety profiles and pharmacokinetic parameters of Amgen’s ABP980 (biosimilar trastuzumab) and pertuzumab administered as an admixture in...
PTEs in Australia – hard lessons for patentees from the Federal Court
Merck Sharp & Dohme Corp. v Sandoz Pty Ltd [2021] FCA 947
Date: 12 August 2021Court: Federal Court of AustraliaJudge: Jagot J Background Under Australian law, a patent term extension (PTE) must be based on the “first regulatory...
Pearce IP BioBlast®: w/e 06 August 2021
29 Jul 21 | US | The American Academy of Ophthalmology pushed back against insurance company pressure to use new bevacizumab biosimilars off-label in eye treatment as...
Pearce IP BioBlast®: w/e 30 July 2021
27 Jul 21 | Abenza and BioXpress Therapeutics announced they have formed a new partnership to support biosimilar development and manufacturing. 28 Jul 21 | Prestige BioPharma...
World-first decision: Artificial Intelligence recognised as a patent inventor under Australian law
The Australian Federal Court in Thaler v Commissioner of Patents [2021] FCA 879 (30 July 2021) has determined that an artificial intelligence (AI) system, DABUS, can be an...
Naomi Pearce one of the world’s “best and brightest Women in IP”
Pearce IP is proud to announce that Principal and Executive Lawyer, Patent Attorney and Trade Mark Attorney Naomi Pearce has been listed by WIPR Diversity as one of the world’s...
Pearce IP BioBlast®: w/e 23 July 2021
19 Jul 21 | Shanghai Henlius Biotech announced that the first patient has been dosed in its Ph I clinical trial of HLX04-O (proposed bevacizumab biosimilar) in the treatment of...
Blockchain technology gets a nod as patentable subject matter
Advanced New Technologies Co., Ltd. [2021] APO 29
Date: 21 July 2021Forum: Australian Patent OfficeDelegate: Ranganath Subbarayan Background Australian Patent Application 2018243625 (Application) in the name of Advanced New...
Pearce IP BioBlast®: w/e 16 July 2021
12 Jul 21 | Boditech Med announced it has obtained export approval for AFIAS Adalimumab, a diagnostic kit which measures adalimumab levels in blood. The test is able to return a...
Pearce IP BioBlast®: w/e 09 July 2021
05 Jul 21 | Chong Kun Dang announced it has signed a commercialisation agreement with Menagen for Nesbell® (biosimilar darbepoetin alfa). Under the agreement, Chong Kun Dang will...
Let the applicant beware!
Misrepresentations are not just limited to examples
Although Australia has taken steps in recent years to harmonise its patent laws with those around the globe, significant differences remain. This means that patent practitioners...
Pearce IP BioBlast®: w/e 02 July 2021
27 Jun 21 | CN | Innovent Biologics announced China’s National Medical Products Administration has approved its supplemental New Drug Application for Tyvyt® (sintilimab) in...
The one-minute guide to life sciences patent eligibility in the US, Europe and Australia
Pearce IP recently reported on the Full Court of the Federal Court decision in Ariosa Diagnostics, Inc v Sequenom, Inc [2021] FCAFC 101, which confirmed that a method of...
Pearce IP celebrates milestone with IAM Patent Ranking
Litigation and Prosecution teams & Leaders ranked among Australia's best
Pearce IP is proud to announce that our team has once again been ranked among the best patent practitioners in Australia by IAM Patent 1000. Both our litigation and prosecution...
Sisters are doin’ it for themselves: female inventors more likely to invent for women
A new report demonstrates that female-dominated inventor teams in biomedical sciences are more likely to invent female-focused inventions, but a lack of majority female inventor...
Recent BioBlast® Updates
Get our Pearce IP Blogs & BioBlast® sent directly to your inbox
Subscribe to our Pearce IP Blogs and BioBlast® to receive our updates via email.